U.S. Markets open in 5 hrs 9 mins
  • S&P Futures

    3,594.00
    -7.50 (-0.21%)
     
  • Dow Futures

    28,815.00
    +14.00 (+0.05%)
     
  • Nasdaq Futures

    10,962.75
    -72.75 (-0.66%)
     
  • Russell 2000 Futures

    1,671.90
    +2.10 (+0.13%)
     
  • Crude Oil

    83.06
    +3.57 (+4.49%)
     
  • Gold

    1,669.90
    -2.10 (-0.13%)
     
  • Silver

    19.32
    +0.28 (+1.48%)
     
  • EUR/USD

    0.9818
    +0.0017 (+0.1767%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    33.02
    +1.18 (+3.71%)
     
  • GBP/USD

    1.1204
    +0.0038 (+0.3384%)
     
  • USD/JPY

    144.9900
    +0.2610 (+0.1803%)
     
  • BTC-USD

    19,187.96
    -98.64 (-0.51%)
     
  • CMC Crypto 200

    435.74
    -7.68 (-1.73%)
     
  • FTSE 100

    6,808.78
    -85.03 (-1.23%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Endo Shares Plunge On Imminent Bankruptcy Filing

·1 min read
  • Endo International plc's (NASDAQ: ENDPQ2 sales decreased 20% to $569.11 million, beating the consensus of $529.94 million.

  • The decrease was attributable to decreased revenues from the Sterile Injectables segment, partially offset by increased revenues from the Generic Pharmaceuticals segment.

  • Sterile Injectables segment revenues fell 58% to $123 million, primarily due to decreased Vasostrict revenues due to lower price and generic competition, channel inventory destocking, and lower overall market volumes as COVID-19-related hospitalizations decline.

  • The company remains in constructive negotiations with its creditors, and it expects that these negotiations will likely result in a pre-arranged filing under Chapter 11 Bankruptcy.

  • Also Read: Endo Weighing Chapter 11 Filing Before Junior Creditors, Opioid Settlements: Report.

  • Generic segment revenues were $203 million, up 22%, attributable to revenues from varenicline tablets.

  • Adjusted income from continuing operations fell 96% to $6.5 million.

  • Adjusted EPS reached $0.03 compared to $0.62 a year ago.

  • Branded pharma segment revenues were $219 million, a decrease of 4%. Specialty Products revenues decreased 2% to $164 million, with Xiaflex increasing 8% to $121 million.

  • Price Action: ENDP shares are down 41.39% at $0.39 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.